{"created":"2023-06-19T10:42:50.076311+00:00","id":2864,"links":{},"metadata":{"_buckets":{"deposit":"f4f3462a-3e89-4283-b891-bf27d59c8452"},"_deposit":{"created_by":3,"id":"2864","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"2864"},"status":"published"},"_oai":{"id":"oai:shiga-med.repo.nii.ac.jp:00002864","sets":["77:78:79"]},"author_link":["494","6327","2909","675","495","674","6322","6321","6456","6320","8708","677"],"item_4_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2015-08","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"358","bibliographicPageStart":"350","bibliographicVolumeNumber":"13","bibliographic_titles":[{},{"bibliographic_title":"Clinical genitourinary cancer","bibliographic_titleLang":"en"}]}]},"item_4_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"野田, 哲史"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"吉田, 哲也"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"影山, 進"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"河内, 明宏"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"平, 大樹"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"森田, 真也"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"寺田, 智祐"}],"nameIdentifiers":[{},{}]}]},"item_4_description_14":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"pdf","subitem_description_type":"Other"}]},"item_4_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background:\nSunitinib has been approved for the treatment of metastatic renal cell carcinoma (RCC). Sunitinib pharmacokinetics shows a large interpatient variability. ","subitem_description_type":"Abstract"},{"subitem_description":"Patients and methods:\nA retrospective, observational clinical study of 21 patients with RCC was performed. Sunitinib was administered for 4 weeks of a 6-week cycle for the first cycle. We evaluated the association of sunitinib-induced toxicities and clinical outcomes with the trough total sunitinib concentration in a steady state during the first cycle. ","subitem_description_type":"Abstract"},{"subitem_description":"Results:\nThe median total sunitinib concentration was 91.8 ng/mL (range, 49.8-205 ng/mL). There was an association between total sunitinib concentration and the severity of thrombocytopenia, anorexia, and fatigue. Patients with ≥ 100 ng/mL total sunitinib (n = 8), compared with patients with < 100 ng/mL (n = 13), had a greater incidence of Grade ≥ 3 toxicities (6 patients [75.0%] vs. 3 patients [23.1%]). Patients with < 100 ng/mL total sunitinib had significantly longer time to treatment failure (TTF) and progression-free survival (PFS) time than patients with ≥ 100 ng/mL (median TTF, 590 vs. 71 days; P = .04; median PFS, 748 vs. 238 days; P = .02). ","subitem_description_type":"Abstract"},{"subitem_description":"Conclusion:\nResults of this study suggest that therapeutic drug monitoring of sunitinib could be useful for avoiding severe toxicities. Dose reduction might be needed, especially when the total sunitinib concentration is ≥ 100 ng/mL, to avoid unnecessary early discontinuation of treatment. ","subitem_description_type":"Abstract"}]},"item_4_description_42":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Journal Article","subitem_description_type":"Other"}]},"item_4_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Elsevier"}]},"item_4_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"25701374","subitem_relation_type_select":"PMID"}}]},"item_4_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.1016/j.clgc.2015.01.007"}],"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1016/j.clgc.2015.01.007","subitem_relation_type_select":"DOI"}}]},"item_4_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2015 Elsevier Inc. All rights reserved. "}]},"item_4_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"NODA, Satoshi"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"OTSUJI, Takashi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"BABA, Masato"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"YOSHIDA, Tetsuya"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"KAGEYAMA, Susumu"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"OKAMOTO, Keisei"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"OKADA, Yusaku"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"KAWAUCHI, Akihiro"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"ONISHI, Hiroyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"HIRA, Daiki"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"MORITA, Shin-ya"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"TERADA, Tomohiro"}],"nameIdentifiers":[{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-02-17"}],"displaytype":"detail","filename":"j.clgc.2015.01.007.pdf","filesize":[{"value":"493.2 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"j.clgc.2015.01.007.pdf","url":"https://shiga-med.repo.nii.ac.jp/record/2864/files/j.clgc.2015.01.007.pdf"},"version_id":"e7764793-6bf2-4386-9cbb-bcfa877650c8"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Sunitinib","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Renal cell carcinoma","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Pharmacokinetics","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Therapeutic drug monitoring","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma."}]},"item_type_id":"4","owner":"3","path":["79"],"pubdate":{"attribute_name":"公開日","attribute_value":"2016-02-18"},"publish_date":"2016-02-18","publish_status":"0","recid":"2864","relation_version_is_last":true,"title":["Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma."],"weko_creator_id":"3","weko_shared_id":3},"updated":"2023-06-19T11:16:36.700312+00:00"}